Sun Pharmaceutical Industries Ltd. Secures South African Approval for Generic Semaglutide Injection Sun Pharmaceutical Industries Ltd. announced on Wednesday, July 15, 2026, that it has obtained regulatory approval from the South African Health Products Regulatory Authority (SAHPRA) to produce and distribute a generic version of semaglutide injection. This approval enables the company to market the drug in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. The decision marks a significant milestone for the pharmaceutical company, which plans to introduce the product to the market in the near future. The generic semaglutide injection will be available in a pre-filled, multi-dose injectable pen format, offering two dosage strengths: 2 mg/1.5 mL and 4 mg/3 mL. This design allows for flexible, once-weekly dosing, simplifying the treatment regimen for patients. The product’s availability is expected to enhance access to effective diabetes management options in South Africa, where the prevalence of type 2 diabetes is rising due to factors such as urbanization and lifestyle changes. Sun Pharmaceutical Industries highlighted that South Africa is the second market, following India, where the company has secured approval for the generic semaglutide. This achievement underscores the company’s capability to develop complex generic medicines that meet rigorous quality standards across diverse regulatory environments. Aalok Shanghvi, the company’s Chief Operating Officer, emphasized the importance of expanding access to affordable, evidence-based treatments.#sun_pharmaceutical_industries_ltd #south_african_health_products_regulatory_authority #aalok_shanghvi #type_2_diabetes_mellitus #semaglutide_injection
